Page 15 - SaxoCell Annual Report22/23

Settlement: In December 2022, the Taiwanese company HAN Biomedical settled in
BioCity Leipzig due to the close cooperation with the SaxoCell project ZellTWund.

Spin-off: TU Dresden spin-off Seamless Therapeutics launches in March 2023 with $12.5M
seed funding to expand a transformative gene editing platform based on programmable
precision designer recombinases at the Dresden site in close collaboration with the
SaxoCell project HemRec.

Awards: In January 2023, SaxoCell member Michael Hudecek (UltraCAR-T) was awarded
the Schelling Prize (endowed at 25,000 euros) by the Bavarian Academy of Sciences for
innovative cancer research in the field of CART cell research. In addition, our project xMac
was awarded for the concept and business plan phase of the Science4Life Venture Cup. In
addition, SaxoCell spokesperson Ulrike Köhl was elected to the Saxon Academy of
Sciences in Leipzig.

New partners: In the current funding phase, we received several partner requests from
companies, which is why we decided to found SaxoCell e.V. to integrate them. In addition,
we are in close exchange with other clusters, such as BioRN and the Cluster4Future
ProxiDrugs (networking meetings planned for the end of 2023). Furthermore, we have
been a network partner of the Tagesspiegel since 2023 in connection with the Future
Medicine Science Match in November 2023.

Public relations: In order to offer low-threshold information on the topic of personalized
medicine to a broad public and to consolidate acceptance of innovative cell and gene
therapies, we participated in public, popular science events such as "Türen auf mit der
Maus" and the "Lange Nacht der Wissenschaften" in Leipzig and Dresden.

10